{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(10)"],"submitter":["Schulman S"],"funding":["International Society on Thrombosis and Haemostasis"],"pubmed_abstract":["Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings. We used the American College of Cardiology Foundation/American Heart Association methodology to assess level of evidence (LOE) and class of recommendation (COR). Only recommendations with LOE A or B were included. Panelists agreed on 12 recommendations: three for non-ho"],"journal":["Journal of thrombosis and haemostasis : JTH"],"pagination":["2214-2225"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9349907"],"repository":["biostudies-literature"],"pubmed_title":["ISTH guidelines for antithrombotic treatment in COVID-19."],"pmcid":["PMC9349907"],"pubmed_authors":["Kaatz S","Bradbury CA","Spyropoulos AC","Connors JM","Middeldorp S","Levy JH","Minichiello T","Schulman S","Iba T","Samama CM","Resnick HE","Sholzberg M","Zarychanski R","Falanga A","Thachil J","Broxmeyer L","Ramacciotti E","International Society on Thrombosis and Haemostasis"],"additional_accession":[]},"is_claimable":false,"name":"ISTH guidelines for antithrombotic treatment in COVID-19.","description":"Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings. We used the American College of Cardiology Foundation/American Heart Association methodology to assess level of evidence (LOE) and class of recommendation (COR). Only recommendations with LOE A or B were included. Panelists agreed on 12 recommendations: three for non-ho","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-03-27T16:14:15.832Z","creation":"2025-08-28T03:07:19.843Z"},"accession":"S-EPMC9349907","cross_references":{"pubmed":["35906716"],"doi":["10.1111/jth.15808"]}}